SCHEMBL6094085

SCHEMBL6094085

O=C(OCc1ccccc1)N(CCCO)c1cccc[n+]1[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.43
PAX8 Q06710 1/20 0.43
ALDH1A1 P00352 5/20 0.37
TDP1 Q9NUW8 2/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
LMNA P02545 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
FABP7 O15540 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859257 0.89 HTT (0.43) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL6853751 0.86 HTT (0.42) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL6095920 0.83 CCR6 (0.35) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL7752775 0.73 CCR6 (0.52) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL1897393 0.72 CCR6 (0.51) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL4194136 0.72 CCR6 (0.51) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL16585962 0.71 CCR6 (0.60) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL12311314 0.70 PAX8 (0.49) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL17747886 0.69 CCR6 (0.48) CCR6PAX8ALDH1A1TDP1MAPK1
SCHEMBL17377997 0.69 CCR6 (0.61) CCR6PAX8ALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7101876-B2 Substituted benzoxazines as integrin antagonists PHARMACIA CORPORATION (US) 2006-09-05 US disclosed
US-20040224948-A1 Novel substituted benzoxazines as integrin antagonists PHARMACIA & UPJOHN S.P.A. (IT) 2004-11-11 US disclosed
US-6750215-B2 ANTITUMOR AGENTS; ANTICANCER AGENTS PHARMACIA & UPJOHN, S.P.A. (IT) 2004-06-15 US disclosed
US-20030073688-A1 Novel substituted benzoxazines as integrin antagonists POLSTER, RACHEL A. 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224948-A1 Novel substituted benzoxazines as integrin antagonists ITGB1, ITGA1, ITGB3 CCR6 2053/4885PAX8 4319/4885ALDH1A1 620/4885
US-20030073688-A1 Novel substituted benzoxazines as integrin antagonists ITGB1, ITGA1, ITGB3 CCR6 2053/4885PAX8 4319/4885ALDH1A1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.